Medtronic reported strong third quarter fiscal year 2026 results, driven by robust organic revenue growth and continued investment in innovation and strategic M&A. The company demonstrated broad-based performance across its portfolios, with particular strength in Cardiovascular and Diabetes segments, positioning it for sustained long-term growth.
Revenue of $9.0 billion increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidance.
positiveCardiovascular Portfolio revenue increased 13.8% as reported and 10.6% organic.
positiveCardiac Ablation Solutions revenue increased 80%, driven by the pulsed field ablation portfolio.
positiveDiabetes business revenue increased 14.8% as reported and 8.3% organic, led by double-digit strength in International markets.
positiveCompany reiterates FY26 organic revenue growth and EPS guidance.
neutralNeuroscience Portfolio revenue increased only 4.1% reported and 2.5% organic, with a flat result in Specialty Therapies.
attentionMedical Surgical Portfolio revenue increased 4.9% as reported and 2.7% organic, with a low-single digit increase in Surgical & Endoscopy.
attentionThe company incurred $77 million in restructuring charges and $62 million in certain litigation charges during the quarter.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total | CC |
|---|---|---|---|---|---|
Cardiovascular | N/A | — | — | — | +10.6% |
Neuroscience | N/A | — | — | — | +2.5% |
Medical Surgical | N/A | — | — | — | +2.7% |
Diabetes | N/A | — | — | — | +8.3% |
| Total Revenue | $0.00M | — | — | 100.0% | — |
Segment performance shows business unit health and growth drivers. Constant currency (CC) removes FX impact for like-for-like comparison.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio.
By unlocking new markets and investing in high-growth opportunities, we are accelerating performance across the company.
Our innovation pipeline and portfolio breadth give us confidence in our ability to sustain long-term growth.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.